These HR/NHEJ kits are cell based, meaning they have the HR or NHEJ GFP reporters pre-installed. A single plasmid (I-Sce1) is transfected to activate repair. Please see this table for a summary and comparison/application of each kit.
Homologous GFP Repair Systems
HeLa Cell HR Kit (I-Sce1 Based)
HeLa Cell HR Kit (CRISPR-CAS Based)
Human Neuroblastoma Cell Line SH-SY5Y using (I-Sce1 transfection)
Mouse 3T3 Cell Line using I-Sce1 transfection
Mouse Neuronal Cell Line using I-Sce1 transfection
Custom construction Kit to make your own HR Cell Reporter
NHEJ GFP Reporter
Systems
Transfection-based HR and NHEJ kits use transient transfections to make a pool of cells containing the DNA reporters to allow the investigator to interrogate the 2 major DNA repair pathways. The advantages are:
A newly published study in the Journal of Molecular Biology (2026) provides important mechanistic insight into how tyrosyl-DNA phosphodiesterase I (Tdp1) processes topoisomerase-mediated DNA damage—extending its functional relevance beyond its classical role in Top1 repair and into the Top2 space.
A new publication in the European Journal of Medicinal Chemistry reports a surprising and important discovery about how certain gold(III) compounds interact with human topoisomerase IIα (Top2α)—and the work was made possible using TopoGEN products.
A groundbreaking new Nature study reveals that cancer cells use specialized genomic “retention elements” to preserve and propagate extrachromosomal circular DNA (ecDNA)—a major engine of oncogene amplification and tumor evolution. These circular ecDNAs, which lack centromeres and segregate randomly, should theoretically be lost at each cell division. Yet this work shows that cancer cells have evolved a mechanism […]
A major Cell paper has uncovered a completely new layer of DNA repair biology: cells use selective autophagy and lysosomes to process and remove Topoisomerase I cleavage complexes (TOP1cc)—the toxic DNA–protein crosslinks created during normal replication and when cells are exposed to TOP1-targeting drugs like camptothecin. According to the Cell article (2024), researchers discovered that: […]
What if the secret to slowing human aging isn’t a mystery at all, but a DNA repair trick stolen from a strange little creature that lives underground? A new Science paper just revealed something jaw-dropping: 👉 Naked mole-rats (also known as the sand puppy 😃) live ~40 years because their DNA repair machinery is turbo-charged […]
They Said This Breast Cancer Was Untouchable. Now It’s 70% Gone! This is why TopoGEN is a key player, providing tools that allow anti-cancer drug discovery and facilitate such important findings. Scientists have designed a new “smart bomb” drug, DM1, that obliterates the deadliest form of breast cancer—triple-negative breast cancer—by hitting two critical targets at […]
Transfection-based Homologous Recombination (HR) and Non-homologous End Joining (NHEJ) kits use transient transfections to make a pool of cells containing the DNA reporters to allow the investigator to interrogate the 2 major DNA repair pathways. The advantages are: It uses GFP readout to measure the efficiency of repair. There is zero background when repair is […]
The anthracycline antibiotics doxorubicin (Adriamycin; DOX) and daunorubicin (DNR) continue to be essential components of first-line chemotherapy in the treatment of a variety of solid and hematopoietic tumors. The overall efficacies of DOX and DNR are, however, impeded by serious dose-limiting toxicities, including cardiotoxicity, and the selection of multiple mechanisms of cellular drug resistance. These […]
The nuclear enzyme DNA topoisomerase II (topo II) is the target of important antitumor agents such as etoposide. Recent work has classified topo II targeting drugs into either topo II poisons that act by stabilizing enzyme-DNA cleavable complexes leading to DNA breaks, or topo II catalytic inhibitors that act at stages in the catalytic cycle […]
This review presents a summary of preclinical and clinical data on the topoisomerase I (topo I) inhibitors that are under clinical development. To date, all of the topo I inhibitors that have been clinically evaluated are analogues of camptothecin, an extract of the Chinese tree Camptotheca acuminata. The therapeutic development of camptothecin was initially limited […]
